Minims Fenylefrinehydrochloride Bausch + Lomb (Phenylephrine Hydrochloride)

Phenylephrine hydrochloride is a selective alpha‑1 adrenergic agonist. When applied to the eye, it binds to alpha‑1 receptors on conjunctival blood‑vessel smooth muscle, causing vasoconstriction. This reduces blood flow to the ocular surface, diminishing the visible redness associated with hyperemia.

The appropriate dose and frequency are determined by the prescribing healthcare professional or according to the product label. Typically, one or two drops are instilled in the affected eye(s) no more than every four to six hours, but exact instructions should be confirmed with a qualified provider.

Safety data for phenylephrine hydrochloride in pregnancy and lactation are limited. Healthcare providers usually weigh potential benefits against unknown risks before recommending use. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using this ophthalmic product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Phenylephrine hydrochloride, the active ingredient in Minims Fenylefrinehydrochloride, is a direct alpha‑1 agonist, offering rapid vasoconstriction. Compared with agents such as naphazoline or tetrahydrozoline, phenylephrine has a similar onset but may have a slightly shorter duration of action and a comparable safety profile when used as directed.

Store Minims Fenylefrinehydrochloride at room temperature, preferably below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and discard any solution that appears discolored or contains particles.

The product is administered as an eye drop. After washing hands, tilt the head back, gently pull down the lower eyelid to create a pocket, and place the prescribed number of drops into the conjunctival sac. Close the eye briefly and avoid blinking excessively to allow absorption.

Serious risks include severe allergic reactions such as anaphylaxis, significant elevation of intra‑ocular pressure that could precipitate glaucoma, and corneal complications like edema or ulceration. Patients experiencing intense pain, vision changes, or swelling should discontinue use and seek immediate medical attention.

Individuals with known hypersensitivity to phenylephrine or any formulation component, patients with narrow‑angle or uncontrolled glaucoma, and those taking monoamine oxidase inhibitors or other potent vasoconstrictors should avoid using this product unless directed by a healthcare professional.